Gabriel Pardo to Female
This is a "connection" page, showing publications Gabriel Pardo has written about Female.
Connection Strength
0.255
-
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.
Score: 0.059
-
Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography. J Clin Neurosci. 2011 Nov; 18(11):1469-72.
Score: 0.031
-
Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate. J Neurosci Nurs. 2010 Feb; 42(1):40-6.
Score: 0.027
-
Arterial compliance in multiple sclerosis: a pilot study. Angiology. 2010 Feb-Mar; 61(1):31-6.
Score: 0.026
-
Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11(4):e200268.
Score: 0.019
-
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. Ann Clin Transl Neurol. 2021 03; 8(3):711-715.
Score: 0.015
-
Evaluation of Power Production Asymmetry during Cycling in Persons with Multiple Sclerosis. Int J Environ Res Public Health. 2019 09 17; 16(18).
Score: 0.013
-
Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 2020 01; 106:102332.
Score: 0.013
-
Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings. Neurol Neuroimmunol Neuroinflamm. 2019 07; 6(4):e582.
Score: 0.013
-
IFN-ß treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015 Mar 01; 194(5):2110-6.
Score: 0.010
-
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15; 341(1-2):22-7.
Score: 0.009
-
Decreased postural balance in multiple sclerosis patients with low disability. Int J Rehabil Res. 2011 Mar; 34(1):53-8.
Score: 0.007
-
A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol. 2011 Mar; 258(3):402-11.
Score: 0.007
-
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007 Jun; 29(6):1128-45.
Score: 0.006